Literature DB >> 9886506

Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles.

J Peñarrubia1, J Balasch, F Fábregues, M Creus, R Casamitjana, J L Ballescá, B Puerto, J A Vanrell.   

Abstract

Gonadotrophin-releasing hormone agonist (GnRHa)-induced ovulation after gonadotrophin ovarian stimulation is used to prevent ovarian hyperstimulation syndrome and multiple pregnancy in polyfollicular cycles. However, one of the major problems to be resolved is corpus luteum function after follicular maturation and ovulation by mid-cycle GnRHa administration. The present report investigated the luteal phase in non-conceptual polyfollicular cycles in 26 patients (group 1) receiving a single dose of 0.5 mg leuprolide acetate to induce ovulation and in a control group of patients (n = 26) (group 2) who were given human chorionic gonadotrophin (HCG) (10,000 IU i.m.) for ovulation induction. All of them were normal ovulatory women undergoing gonadotrophin ovarian stimulation because of unexplained infertility or male factor. In both groups of patients two doses of 2500 IU HCG i.m. were given 6 and 10 days after the ovulatory dose of HCG or GnRHa to support the luteal phase. All cycles were ovulatory as shown by mid-luteal serum progesterone concentrations >10 ng/ml. Mean serum progesterone concentrations were 62% higher in group 2 than in group 1, but this difference was not statistically significant. The mean length of the luteal phase was similar in groups 1 and 2. It is concluded that HCG luteal support is a useful tool to overcome the luteal phase inadequacy that characterizes GnRHa-triggered cycles after gonadotrophin stimulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886506     DOI: 10.1093/humrep/13.12.3315

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

Review 1.  Luteal phase support for women trying to conceive by intrauterine insemination or sexual intercourse.

Authors:  Lingling Salang; Danielle M Teixeira; Ivan Solà; Jen Sothornwit; Wellington P Martins; Magdalena Bofill Rodriguez; Pisake Lumbiganon
Journal:  Cochrane Database Syst Rev       Date:  2022-08-24

2.  Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial.

Authors:  Saghar Salehpour; Maryam Tamimi; Nasrin Saharkhiz
Journal:  Iran J Reprod Med       Date:  2013-11

Review 3.  Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.

Authors:  Juan Carlos Castillo; Thor Haahr; María Martínez-Moya; Peter Humaidan
Journal:  Ups J Med Sci       Date:  2020-05-04       Impact factor: 2.384

Review 4.  Individualized luteal phase support after fresh embryo transfer: unanswered questions, a review.

Authors:  Jing Zhao; Jie Hao; Yanping Li
Journal:  Reprod Health       Date:  2022-01-22       Impact factor: 3.223

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.